Advertisement

Development of Relugolix Combination Therapy as a Medical Treatment Option for Women with Uterine Fibroids or Endometriosis

Open AccessPublished:November 21, 2022DOI:https://doi.org/10.1016/j.xfre.2022.11.010
      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      Treatment of uterine fibroids (UF) and endometriosis (EM) has relied on the surgical skills of gynecologists to improve symptoms and potentially alter the course of these debilitating diseases. Medical management of symptoms for both diseases leverages combined hormonal contraceptives used off label as first-line treatment, with NSAIDs and opioids to manage pain as needed. Gonadotropin-releasing hormone (GnRH) receptor agonists (peptide analogs) have been used as short-term therapy to manage severe symptoms of UF or EM, or to treat anemia or reduce fibroid size prior to surgery. The introduction of oral GnRH receptor antagonists opened the door for development of new treatment options for UF, EM, and other estrogen-driven diseases.
      Relugolix is an orally active, non-peptide, GnRH receptor antagonist that competitively binds to GnRH receptors, preventing the release of follicle-stimulating hormone (FSH) and luteinising hormone (LH) into the systemic circulation. In women, the reduction in FSH concentrations prevent natural follicular development, suppressing ovarian production of estrogen, and together with reductions in LH concentrations, prevent ovulation and corpus-luteum formation and, thereby, the production of progesterone (P). By reducing circulating concentrations of E2 and P, relugolix improves HMB and other symptoms associated with UF and moderate to severe pain associated with EM, including dysmenorrhea, non-menstrual pelvic pain (NMPP), and dyspareunia. However, as monotherapy, use of relugolix is associated with signs and symptoms of a hypoestrogenic state, including bone mineral density (BMD) loss and vasomotor symptoms. The clinical development of relugolix incorporated the addition of a 1-mg dose of E2 and a 0.5-mg dose of NETA to achieve systemic E2 concentrations that remain in a therapeutic range, while mitigating the risk for BMD loss and vasomotor symptoms, enabling longer-term treatment and reducing the impact of symptoms on quality of life, and potentially delaying or preventing the need for surgery.
      Relugolix 40 mg in combination with estradiol (E2) 1 mg and norethindrone acetate (NETA) 0.5 mg as a single fixed-dose combination tablet (relugolix combination therapy [relugolix-CT]) approved in the United States (US) as MYFEMBREE® is the first and only once-daily oral GnRH antagonist combination therapy indicated for the management of heavy menstrual bleeding (HMB) associated with UF and moderate to severe pain associated with EM. In the European Union (EU) and the United Kingdom (UK) relugolix-CT is approved as RYEQO® for management of symptoms associated with UF. In Japan, relugolix 40 mg, as monotherapy, was the first GnRH receptor antagonist approved to improve symptoms associated with UF or pain associated with EM under the brand name RELUMINA®.
      In men, relugolix suppresses testosterone production. Relugolix 120 mg (ORGOVYX®) was developed by Myovant Sciences and is approved in the US, EU and UK as the first and only oral androgen-deprivation therapy for the treatment of advanced prostate cancer.
      This review is focused on the development of relugolix and relugolix-CT in women’s health indications.

      Keywords